本文選題：上皮性卵巢癌 + 轉(zhuǎn)化生長(zhǎng)因子��； 參考：《河北醫(yī)科大學(xué)》2015年碩士論文

【摘要】：目的:通過檢測(cè)上皮性卵巢癌中TGF-β1的表達(dá),分析TGF-β1與MDR1、PTEN、TOPOII、ERCC1、LIVIN耐藥相關(guān)基因的相關(guān)性,篩選出與TGF-β1相關(guān)的耐藥基因,希望通過多基因聯(lián)合檢測(cè)更客觀全面的指導(dǎo)臨床用藥,降低耐藥性,提高患者生存率,TGF-β1將成為卵巢癌耐藥的分子標(biāo)記及治療的新靶點(diǎn)。方法:采用免疫組化方法分別檢測(cè)TGF-β1在上皮性卵巢癌組(50例)、卵巢良性腫瘤組(20例)、正常卵巢組(20例)的表達(dá)情況,回顧分析相應(yīng)組織切片中MDR1、PTEN、TOPOII、ERCC1、LIVIN耐藥相關(guān)基因與TGF-β1的表達(dá)相關(guān)性,統(tǒng)計(jì)軟件選用SPSS19.0,計(jì)數(shù)資料應(yīng)用χ2檢驗(yàn),采用Spearman等級(jí)相關(guān)進(jìn)行相關(guān)性分析,均以P0.05表示差異具有統(tǒng)計(jì)學(xué)意義。結(jié)果:1 TGF-β1在上皮性卵巢癌中的表達(dá)TGF-β1陽(yáng)性表達(dá)主要定位于細(xì)胞漿,呈棕黃色顆粒染色。在20例正常卵巢組中TGF-β1有4例呈現(xiàn)出陽(yáng)性表達(dá),陽(yáng)性表達(dá)率為20%(4/20例);在20例卵巢良性腫瘤組中TGF-β1有8例呈現(xiàn)出陽(yáng)性表達(dá),陽(yáng)性表達(dá)率為40%(8/20例);在50例上皮性卵巢癌組中TGF-β1有38例呈現(xiàn)出陽(yáng)性表達(dá),陽(yáng)性表達(dá)率為76%(38/50例);TGF-β1的陽(yáng)性表達(dá)率在逐步上升。上皮性卵巢癌組TGF-β1的表達(dá)與正常卵巢組TGF-β1的表達(dá)進(jìn)行比較,差異有顯著性,具有統(tǒng)計(jì)學(xué)意義(P0.05);上皮性卵巢癌組TGF-β1的表達(dá)與卵巢良性腫瘤組TGF-β1的表達(dá)進(jìn)行比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05);正常卵巢組TGF-β1的表達(dá)與卵巢良性腫瘤組TGF-β1的表達(dá)進(jìn)行比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。2上皮性卵巢癌組織中TGF-β1的表達(dá)與臨床病理特性的關(guān)系2.1年齡在28例年齡≥50歲的卵巢上皮性癌組織中TGF-β1陽(yáng)性表達(dá)率為78.5%(22/28),在22例年齡50歲的卵巢上皮性癌組織中的TGF-β1陽(yáng)性表達(dá)率為72.7%(16/22),二者比較差異無統(tǒng)計(jì)學(xué)意義(χ2=0.231,P0.05)2.2分期在34例Ⅲ-Ⅳ期卵巢癌中TGF-β1陽(yáng)性表達(dá)率88.2%(30/34),16例Ⅰ期-Ⅱ期卵巢癌中TGF-β1陽(yáng)性表達(dá)率50.0%(8/16),兩者比較差異有統(tǒng)計(jì)學(xué)意義(χ2=8.720,P0.05)2.3組織學(xué)類型在24例漿液性囊腺癌中TGF-β1陽(yáng)性表達(dá)率79.2%(19/24),16例粘液性囊腺癌中TGF-β1陽(yáng)性表達(dá)率68.8%(11/16),10例卵巢子宮內(nèi)膜樣癌中TGF-β1陽(yáng)性表達(dá)率80.0%(8/10),三者之間比較差異無統(tǒng)計(jì)學(xué)意義(χ2=0.739,P0.05);2.4組織病理分化程度在24例高中分化組中TGF-β1陽(yáng)性表達(dá)率66.7%(16/24例),26例低分化組中TGF-β1陽(yáng)性表達(dá)率84.6%(22/26例),二者比較差異無統(tǒng)計(jì)學(xué)意義(χ2=2.204,P0.05)。2.5淋巴結(jié)轉(zhuǎn)移在32例淋巴結(jié)有轉(zhuǎn)移組中TGF-β1陽(yáng)性表達(dá)率81.3%(26/32例),18例有淋巴結(jié)無轉(zhuǎn)移組中TGF-β1陽(yáng)性表達(dá)率66.7%(12/18例),二者比較差異無統(tǒng)計(jì)學(xué)意義(χ2=0.663,P0.05)。3 TGF-β1的表達(dá)與MDR1、PTEN、TOPOII、ERCC1、LIVIN耐藥相關(guān)基因的關(guān)系TGF-β1與MDR1兩者的表達(dá)具有正相關(guān)性(r=0.322,P0.05)。TGF-β1與PTEN兩者的表達(dá)具有負(fù)相關(guān)性(r=-0.668,P0.05)。TGF-β1與TOPOII兩者的表達(dá)無相關(guān)性(r=-0.506,P=0.078)。TGF-β1與ERCC1兩者的表達(dá)無相關(guān)性(r=-0.037,P=0.636)。TGF-β1與LIVIN兩者的表達(dá)無相關(guān)性(r=-0.801,P=0.21)。結(jié)論:1 TGF-β1在上皮性卵巢癌中陽(yáng)性表達(dá)水平很高,卵巢良性腫瘤和正常卵巢TGF-β1陽(yáng)性表達(dá)水平都比上皮性卵巢癌低,正常卵巢組織、卵巢良性腫瘤、上皮性卵巢癌,TGF-β1的表達(dá)情況呈逐漸升高趨勢(shì),表明TGF-β1在卵巢組織由良性向惡性發(fā)展的過程中起了重要作用,TGF-β1可作為診斷上皮性卵巢癌的生物學(xué)指標(biāo)。2卵巢癌組織中TGF-β1的表達(dá)與患者年齡大小、組織學(xué)的類型、組織病理分化程度、是否出現(xiàn)淋巴結(jié)轉(zhuǎn)移無相關(guān)性,而與臨床分期呈現(xiàn)正相關(guān)性。表明TGF-β1與卵巢癌的疾病進(jìn)展相關(guān)。3上皮性卵巢癌中TGF-β1與MDR1的表達(dá)呈正相關(guān),提示其在腫瘤的發(fā)生、發(fā)展中具有相互協(xié)同作用。TGF-β1與PTEN的表達(dá)呈負(fù)相關(guān),說明其與PTEN相互拮抗。
[Abstract]:Objective: to determine the correlation between TGF- beta 1 and MDR1, PTEN, TOPOII, ERCC1, LIVIN resistance related genes, and to screen out the resistance genes related to TGF- beta 1 by detecting the expression of TGF- beta 1 in epithelial ovarian cancer, and to select the drug resistant genes related to TGF- beta 1. Methods: the expression of TGF- beta 1 in epithelial ovarian cancer group (50 cases), ovarian benign tumor group (20 cases) and normal ovarian group (20 cases) were detected by immunohistochemical method. The expression of MDR1, PTEN, TOPOII, ERCC1, LIVIN resistance related genes and the expression of TGF- beta 1 in the corresponding tissue sections were analyzed. Correlation, the statistical software was selected by SPSS19.0, the count data were tested by chi 2, and the correlation analysis of Spearman grade was used to analyze the correlation. The difference was statistically significant by P0.05. Results: the expression of 1 TGF- beta 1 in epithelial ovarian cancer was mainly located in the cytoplasm and stained with brown yellow granules, in 20 normal ovarian groups. In TGF- beta 1, 4 cases showed positive expression, positive expression rate was 20% (4/20 cases), and 8 cases of TGF- beta 1 in 20 cases of ovarian benign tumor showed positive expression, the positive expression rate was 40% (8/20 cases); in 50 cases of epithelial ovarian cancer, 38 cases of TGF- beta 1 showed positive expression, the positive expression rate was 76% (38/50 cases); the positive expression rate of TGF- beta 1 The expression of TGF- beta 1 in the epithelial ovarian cancer group was compared with the expression of TGF- beta 1 in the normal ovarian group, and the difference was statistically significant (P0.05). The expression of TGF- beta 1 in the epithelial ovarian cancer group was compared with the expression of TGF- beta 1 in the benign ovarian tumor group (P0.05); the expression of TGF- beta 1 in the normal ovarian group was the expression of TGF- beta 1. Compared with the expression of TGF- beta 1 in the benign ovarian tumor group, the difference was not statistically significant (P0.05), the relationship between the expression of TGF- beta 1 and the clinicopathological characteristics in the epithelial ovarian cancer tissue of.2 2.1 age was 78.5% (22/28) in 28 cases of ovarian epithelial carcinoma with age 50 years old (78.5% (22/28), and in 22 cases of ovarian epithelial carcinoma, age 50 years old. The positive expression rate of TGF- beta 1 in the tissue was 72.7% (16/22), and there was no statistical difference between the two groups (x 2=0.231, P0.05) 2.2 stage in 34 cases of stage III - IV ovarian cancer 88.2% (30/34), and 16 cases of stage I - II ovarian cancer, the positive rate of TGF- beta 1 was 50% (8/16), and the difference was statistically significant (chi 2=8.720, P0.05) 2.3. The positive expression rate of TGF- beta 1 in 24 serous cystadenocarcinoma was 79.2% (19/24), and the positive expression rate of TGF- beta 1 in 16 cases of mucinous cystadenocarcinoma was 68.8% (11/16). The positive rate of TGF- beta 1 in 10 cases of ovarian endometrioid carcinoma was 80% (8/10), and there was no significant difference between three (x 2=0.739, P0.05), and 2.4 tissue pathological differentiation was in 24. The positive expression rate of TGF- beta 1 in the high school group was 66.7% (16/24), and the positive expression rate of TGF- beta 1 in 26 low differentiation groups was 84.6% (22/26 case). The two cases had no statistical difference (x 2=2.204, P0.05).2.5 lymph node metastasis in 32 cases of lymph node metastasis group, the positive rate of TGF- beta 1 was 81.3% (26/32 cases), 18 cases had TGF- beta 1 in the lymph node without metastasis group. The positive expression rate was 66.7% (12/18), and there was no statistical difference between the two (x, P0.05).3 TGF- beta 1. The relationship between the expression of MDR1, PTEN, TOPOII, ERCC1, LIVIN resistance genes was positively correlated with the expression of MDR1. There was no correlation between the expression of OPOII (r=-0.506, P=0.078) and the expression of.TGF- beta 1 and ERCC1 (r=-0.037, P=0.636), and there was no correlation between the expression of.TGF- beta 1 and LIVIN (r=-0.801, P=0.21). Conclusion: the positive expression level of 1 TGF- beta 1 in epithelial ovarian cancer is high, and the positive expression level of the benign ovarian tumor and normal ovary is 1. Lower than epithelial ovarian cancer, normal ovarian tissue, benign ovarian tumor, epithelial ovarian cancer, and TGF- beta 1, the expression of TGF- beta 1 in the ovarian tissue from benign to malignant development plays an important role, TGF- beta 1 can be used as a biological indicator for the diagnosis of epithelial oval carcinoma of.2, TGF- beta 1 in ovarian cancer tissue There is no correlation between the age size, the type of histology, the degree of histology, the degree of histopathological differentiation, and the occurrence of lymph node metastasis, but there is a positive correlation with the clinical stages. It shows that the expression of TGF- beta 1 in TGF- beta 1 is positively related to the expression of MDR1 in the epithelial ovarian cancer of ovarian cancer, suggesting that it is in the development of the tumor. .TGF- PTEN 1 is negatively correlated with the expression of PTEN, indicating that they interact with each other.

【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 趙紅霞;;PTEN與腫瘤的相關(guān)性研究進(jìn)展[J];武漢大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2014年01期

2 袁莉;趙輝;李琳;王衛(wèi)華;;TGF-α和PTEN在非小細(xì)胞肺癌中的表達(dá)及意義[J];菏澤醫(yī)學(xué)�？茖W(xué)校學(xué)報(bào);2013年02期

3 劉彩艷;曲們們;;IGF-ⅠTGF-β1在卵巢上皮性腫瘤中的表達(dá)及與微血管密度的關(guān)系[J];中國(guó)腫瘤臨床;2012年18期

4 王超;譚文華;劉巍;劉艷勃;;TopoⅡα和抑癌基因PTEN在卵巢上皮性癌中的表達(dá)及其意義[J];中國(guó)優(yōu)生與遺傳雜志;2012年07期

5 馬穎;楊向紅;田保玲;林連捷;;大腸腫瘤中PTEN和TGF-β_1表達(dá)及意義[J];中國(guó)組織化學(xué)與細(xì)胞化學(xué)雜志;2012年01期

6 蔡冬梅;劉蓉;;轉(zhuǎn)化生長(zhǎng)因子-β1在上皮性卵巢癌中的表達(dá)及意義[J];交通醫(yī)學(xué);2011年03期

7 馬鵬;曹曉燕;馮義朝;;PTEN蛋白表達(dá)與胃癌預(yù)后的關(guān)系[J];延安大學(xué)學(xué)報(bào)(醫(yī)學(xué)科學(xué)版);2010年02期

8 黃海玉;劉小樂;陳衡;彭碧玲;;PTEN和FHIT在上皮性卵巢腫瘤中的表達(dá)及其臨床意義[J];中國(guó)婦幼保健;2010年05期

9 劉娟;生秀杰;;TGF-β1在卵巢上皮性癌的表達(dá)水平及意義[J];現(xiàn)代腫瘤醫(yī)學(xué);2010年01期

10 蔣勝;李力;張瑋;唐兆前;王琪;姚德生;張潔清;陽(yáng)志軍;;ERCC1基因mRNA表達(dá)水平在卵巢上皮性癌組織中的意義[J];實(shí)用婦產(chǎn)科雜志;2009年11期

，

本文編號(hào)：1894094